Detail akcie Alkermes online

Business Summary: Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Alkermes Plc revenues decreased 5% to $1.48B. Net income before extraordinary items decreased 35% to $241.7M. Revenues reflect Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA segment decrease of 54% to $109.6M, Manufacturing-Other segment decrease of 83% to $9.9M, Rest of the World segment decrease of 30% to $102.4M, United States segment decrease of 3% to $1.37B.